Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WT-gag-TCR modified T cells · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir \>200 and a recorded historical viral load setpoint, will receive a WT-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption. |
| Arm 2 | EXPERIMENTAL | Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir \>200 and a recorded historical viral load setpoint, will receive a α/6-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption. |
| Arm 3 | EXPERIMENTAL | Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir \>200. Subject will undergo an 16 week treatment interruption during which a single infusion of WT-gag-TCR modified autologous T cells at 8 weeks post STI. |
| Arm 4 | EXPERIMENTAL | Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir of \>200. Subject will undergo a 16-week treatment interruption during which a single infusion of α/6-gag-TCR modified autologous T cells at 8 weeks post STI. |
| Name | Type | Description |
|---|---|---|
| WT-gag-TCR modified T cells | BIOLOGICAL | Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days. |
| α/6-gag-TCR modified T cells | BIOLOGICAL | Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days. |
| STI or Drug Holiday | OTHER | Subjects will stop taking antiviral medications for 16 weeks. |
Inclusion Criteria: * Age 18 years or older * Karnofsky Performance of 80 or higher * HLA-A2 Positive * Chronic HIV-1 infection * On stable HAART regimen (with no changes within 4 weeks of study entry) * Willing to undergo a limited treatment interruption of antiretroviral medication * CD4+ T cell ...
Top 20 of 28 competitors
WT-gag-TCR modified T cells is an investigational cell therapy being studied for the treatment of HIV infections. It is a monoclonal antibody modality currently in Phase 1 clinical development. The therapy is designed to target HIV through genetically modified T cells, though it remains investigational and is not yet approved.
WT-gag-TCR modified T cells targets the HIV Gag protein. The therapy involves redirecting high-affinity Gag-specific autologous T cells to recognize and attack HIV-infected cells. This approach is being evaluated in a Phase 1 clinical trial for patients with HIV infections.
WT-gag-TCR modified T cells is being developed by Adaptimmune Therapeutics PLC, which trades under the ticker ADAP. The company is conducting clinical research on this investigational therapy for HIV infections, with the therapy currently in Phase 1 development.
WT-gag-TCR modified T cells is in Phase 1 clinical development. It is an investigational therapy for HIV infections and has not been approved by regulatory authorities. The Phase 1 trial has been completed, with a total enrollment of 2 participants.
WT-gag-TCR modified T cells has one completed Phase 1 clinical trial, identified as NCT00991224, titled 'Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy.' The trial enrolled 2 participants with HIV infections in the United States and was a controlled, non-randomized study.
Yes, WT-gag-TCR modified T cells is the same as redirected high affinity Gag-specific autologous T cells. The clinical trial NCT00991224 uses this description to refer to the therapy, which involves genetically modified T cells targeting the HIV Gag protein for the treatment of HIV infections.